Bonnia Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bonnia Liu has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Christopher McMaster
Department of Clinical Pharmacology, Austin Health, Level 5, Lance Townsend Building, Studley Rd, Heidelberg, VIC, 3084, Australia.
2 shared publications - Claire Elizabeth Owen
Department of Rheumatology Austin Health Melbourne Victoria Australia
2 shared publications - David F. L. Liew
Department of Rheumatology, Austin Health, Melbourne, Australia
2 shared publications - Jessica L. Leung
Department of Medicine University of Melbourne Melbourne Victoria Australia
2 shared publications - Andor W. J. M. Glaudemans
Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
1 shared publication Andrew M. Scott
Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia
1 shared publication
Latest Publications
- Open Access
- 8 April 2026
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 56 (4) , 593-605
PET imaging of polymyalgia rheumatica: update and future trends
- 8 April 2026
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 56 (4) , 593-605
Open AccessPET imaging of polymyalgia rheumatica: update and future trends
- 6 December 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (5) , 3238-3245
Polymyalgia rheumatica patients presenting with atypical clinical features still exhibit characteristic 18F-FDG PET/CT findings
Purpose The utility of 18F-fluorodeoxyglucose positron emission tomography with low-dose computed tomography (18F-FDG PET/CT) to diagnose patients with atypical features but clinically confirmed PMR is unknown. This study explored 18F-FDG PET/CT findings among atypical PMR cases and contrasted results with a typical PMR population. The performance of an AI model for PMR diagnosis was also tested. Methods Natural language processing searched the electronic data warehouse at our institution for 18F-FDG PET/CT reports with PMR findings. Medical record review confirmed the clinical diagnosis for potential cases. Required entry Criteria of the 2012 EULAR/ACR Classification for PMR (age ≥50 years, bilateral shoulder aching and abnormal CRP and/or ESR) stratified patients as “typical” or“atypical”. Qualitative and semi-quantitative (SUVmax) scoring of 18F-FDG uptake at characteristic musculoskeletal sites was undertaken for steroid-naïve, atypical PMR patients and compared with results for steroid-naïve, typical cases from an earlier study. A ResNet50 AI model was tested on the atypical cohort’s images, with GradCam maps generated and cross-checked by an experienced clinician. Results 225 18F-FDG PET/CT reports were retrieved from >38,000 scans; 121 patients had a clinical PMR diagnosis. Seventeen steroid-naïve, atypical cases were compared with 35 steroid-naïve, typical patients. The frequency of abnormalities at key musculoskeletal sites was similar between groups, however mean SUVmaxwas significantly higher in the typical cohort. The AI model identified a PMR diagnosis in 16/17 (94.1%) atypical patients. Conclusion Characteristic findings of PMR are appreciated on 18F-FDG PET/CT among atypical patients, but avidity is reduced. AI technology can reliably detect this imaging pattern. Words: 249 (max. 250).
- 6 December 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (5) , 3238-3245
Polymyalgia rheumatica patients presenting with atypical clinical features still exhibit characteristic 18F-FDG PET/CT findings
Purpose The utility of 18F-fluorodeoxyglucose positron emission tomography with low-dose computed tomography (18F-FDG PET/CT) to diagnose patients with atypical features but clinically confirmed PMR is unknown. This study explored 18F-FDG PET/CT findings among atypical PMR cases and contrasted results with a typical PMR population. The performance of an AI model for PMR diagnosis was also tested. Methods Natural language processing searched the electronic data warehouse at our institution for 18F-FDG PET/CT reports with PMR findings. Medical record review confirmed the clinical diagnosis for potential cases. Required entry Criteria of the 2012 EULAR/ACR Classification for PMR (age ≥50 years, bilateral shoulder aching and abnormal CRP and/or ESR) stratified patients as “typical” or“atypical”. Qualitative and semi-quantitative (SUVmax) scoring of 18F-FDG uptake at characteristic musculoskeletal sites was undertaken for steroid-naïve, atypical PMR patients and compared with results for steroid-naïve, typical cases from an earlier study. A ResNet50 AI model was tested on the atypical cohort’s images, with GradCam maps generated and cross-checked by an experienced clinician. Results 225 18F-FDG PET/CT reports were retrieved from >38,000 scans; 121 patients had a clinical PMR diagnosis. Seventeen steroid-naïve, atypical cases were compared with 35 steroid-naïve, typical patients. The frequency of abnormalities at key musculoskeletal sites was similar between groups, however mean SUVmaxwas significantly higher in the typical cohort. The AI model identified a PMR diagnosis in 16/17 (94.1%) atypical patients. Conclusion Characteristic findings of PMR are appreciated on 18F-FDG PET/CT among atypical patients, but avidity is reduced. AI technology can reliably detect this imaging pattern. Words: 249 (max. 250).
- 7 December 2023
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 51 (5) , 1287-1296
FDG-PET/CT for investigation of pyrexia of unknown origin: a cost of illness analysis
Background Our study aims to explore the current utilisation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in the diagnostic pathway of pyrexia of unknown origin (PUO) and associated cost of illness in a large tertiary teaching hospital in Australia. Method 1257 febrile patients between June 2016 and September 2022 were retrospectively reviewed. There were 57 patients who met the inclusion criteria of “classical PUO”, of which FDG-PET/CT was performed in 31 inpatients, 15 outpatients and 11 inpatients did not have an FDG-PET/CT scan. The patient demographics, clinical characteristics and inpatient cost were analysed, together with the diagnostic performance of FDG-PET/CT and impact on clinical management. Result The mean age, length of stay and total cost of admission were higher for inpatients who received FDG-PET/CT versus those who did not. The median cost per patient-bed-day did not differ between the two groups. Inpatients who received earlier FDG-PET/CTs (≤ 7 days from admission) had shorter length of stays and lower total cost compared to those who received a later scan. A negative FDG-PET/CT scan, demonstrating no serious or life-threatening abnormalities resulted in subsequent discharge from hospital or outpatient clinic in 7/10 (70%) patients. There were 11/40 (28%) scans where ancillary abnormalities were identified, requiring further evaluation. Conclusion FDG-PET/CT showed high diagnostic accuracy and significant impact on patient management in patients with PUO. FDG-PET/CT performed earlier in admission for PUO was associated with shorter length of stay and lower total cost.
- 7 December 2023
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 51 (5) , 1287-1296
FDG-PET/CT for investigation of pyrexia of unknown origin: a cost of illness analysis
Background Our study aims to explore the current utilisation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in the diagnostic pathway of pyrexia of unknown origin (PUO) and associated cost of illness in a large tertiary teaching hospital in Australia. Method 1257 febrile patients between June 2016 and September 2022 were retrospectively reviewed. There were 57 patients who met the inclusion criteria of “classical PUO”, of which FDG-PET/CT was performed in 31 inpatients, 15 outpatients and 11 inpatients did not have an FDG-PET/CT scan. The patient demographics, clinical characteristics and inpatient cost were analysed, together with the diagnostic performance of FDG-PET/CT and impact on clinical management. Result The mean age, length of stay and total cost of admission were higher for inpatients who received FDG-PET/CT versus those who did not. The median cost per patient-bed-day did not differ between the two groups. Inpatients who received earlier FDG-PET/CTs (≤ 7 days from admission) had shorter length of stays and lower total cost compared to those who received a later scan. A negative FDG-PET/CT scan, demonstrating no serious or life-threatening abnormalities resulted in subsequent discharge from hospital or outpatient clinic in 7/10 (70%) patients. There were 11/40 (28%) scans where ancillary abnormalities were identified, requiring further evaluation. Conclusion FDG-PET/CT showed high diagnostic accuracy and significant impact on patient management in patients with PUO. FDG-PET/CT performed earlier in admission for PUO was associated with shorter length of stay and lower total cost.
- 18 November 2022
- Published by Elsevier in The Lancet Rheumatology
- Vol. 5 (1) , e8-e10
Better diagnostic tools needed for biopsy-negative giant cell arteritis
- 18 November 2022
- Published by Elsevier in The Lancet Rheumatology
- Vol. 5 (1) , e8-e10
Better diagnostic tools needed for biopsy-negative giant cell arteritis